Detection of Cannabinoids in Oral Fluid Specimens As the Preferred Biological Matrix for a Point-of-Care Biosensor Diagnostic Device

Overview

Journal Biosensors (Basel)

Specialty Biotechnology

Date 2024 Mar 27

PMID 38534233

Authors

Calin Trif

Dorin Harpaz

Evgeni Eltzov

Yardnapar Parcharoen

Chiravoot Pechyen

Robert S Marks

Affiliations

Soon will be listed here.

Abstract

An increasing number of countries have started to decriminalize or legalize the consumption of cannabis for recreational and medical purposes. The active ingredients in cannabis, termed cannabinoids, affect multiple functions in the human body, including coordination, motor skills, memory, response time to external stimuli, and even judgment. Cannabinoids are a unique class of terpeno-phenolic compounds, with 120 molecules discovered so far. There are certain situations when people under the influence of cannabis may be a risk to themselves or the public safety. Over the past two decades, there has been a growing research interest in detecting cannabinoids from various biological matrices. There is a need to develop a rapid, accurate, and reliable method of detecting cannabinoids in oral fluid as it can reveal the recent intake in comparison with urine specimens, which only show a history of consumption. Significant improvements are continuously made in the analytical formats of various technologies, mainly concerning improving their sensitivity, miniaturization, and making them more user-friendly. Additionally, sample collection and pretreatment have been extensively studied, and specific devices for collecting oral fluid specimens have been perfected to allow rapid and effective sample collection. This review presents the recent findings regarding the use of oral fluid specimens as the preferred biological matrix for cannabinoid detection in a point-of-care biosensor diagnostic device. A critical review is presented, discussing the findings from a collection of review and research articles, as well as publicly available data from companies that manufacture oral fluid screening devices. Firstly, the various conventional methods used to detect cannabinoids in biological matrices are presented. Secondly, the detection of cannabinoids using point-of-care biosensors is discussed, emphasizing oral fluid specimens. This review presents the current pressing technological challenges and highlights the gaps where new technological solutions can be implemented.

References

Bylda C, Leinenbach A, Thiele R, Kobold U, Volmer D . Development of an electrospray LC-MS/MS method for quantification of Δ(9) -tetrahydrocannabinol and its main metabolite in oral fluid. Drug Test Anal. 2012; 4(7-8):668-74. DOI: 10.1002/dta.1334. View

Gjerde H, Langel K, Favretto D, G Verstraete A . Estimation of equivalent cutoff thresholds in blood and oral fluid for drug prevalence studies. J Anal Toxicol. 2014; 38(2):92-8. DOI: 10.1093/jat/bkt122. View

Huestis M, Smith M . Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. Trends Mol Med. 2018; 24(2):156-172. DOI: 10.1016/j.molmed.2017.12.006. View

Beckham J, Adkisson K, Hertzberg J, Kimbrel N, Budney A, Stephens R . Mobile contingency management as an adjunctive treatment for co-morbid cannabis use disorder and cigarette smoking. Addict Behav. 2017; 79:86-92. PMC: 5807114. DOI: 10.1016/j.addbeh.2017.12.007. View

Teixeira H, Verstraete A, Proenca P, Corte-Real F, Monsanto P, Vieira D . Validated method for the simultaneous determination of Delta9-THC and Delta9-THC-COOH in oral fluid, urine and whole blood using solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionization. Forensic Sci Int. 2007; 170(2-3):148-55. DOI: 10.1016/j.forsciint.2007.03.026. View

Agius R, Nadulski T, Moore C . Validation of LUCIO-Direct-ELISA kits for the detection of drugs of abuse in urine: application to the new German driving licence re-granting guidelines. Forensic Sci Int. 2011; 215(1-3):38-45. DOI: 10.1016/j.forsciint.2011.10.034. View

Quintela O, Crouch D, Andrenyak D . Recovery of drugs of abuse from the Immunalysis Quantisal oral fluid collection device. J Anal Toxicol. 2006; 30(8):614-6. DOI: 10.1093/jat/30.8.614. View

Rohrich J, SCHIMMEL I, Zorntlein S, Becker J, Drobnik S, Kaufmann T . Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. J Anal Toxicol. 2010; 34(4):196-203. DOI: 10.1093/jat/34.4.196. View

Niedbala R, Feindt H, Kardos K, Vail T, Burton J, Bielska B . Detection of analytes by immunoassay using up-converting phosphor technology. Anal Biochem. 2001; 293(1):22-30. DOI: 10.1006/abio.2001.5105. View

10.

Kauert G, Iwersen-Bergmann S, Toennes S . Assay of Delta9-tetrahydrocannabinol (THC) in oral fluid-evaluation of the OraSure oral specimen collection device. J Anal Toxicol. 2006; 30(4):274-7. DOI: 10.1093/jat/30.4.274. View

11.

Petrilli K, Hines L, Adams S, Morgan C, Curran H, Freeman T . High potency cannabis use, mental health symptoms and cannabis dependence: Triangulating the evidence. Addict Behav. 2023; 144:107740. DOI: 10.1016/j.addbeh.2023.107740. View

12.

Crouch D . Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int. 2005; 150(2-3):165-73. DOI: 10.1016/j.forsciint.2005.02.028. View

13.

Heltsley R, DePriest A, Black D, Crouch D, Robert T, Marshall L . Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens. J Anal Toxicol. 2012; 36(2):75-80. DOI: 10.1093/jat/bkr019. View

14.

Richeval C, Dumestre-Toulet V, Wiart J, Vanhoye X, Humbert L, Nachon-Phanithavong M . New psychoactive substances in oral fluid of drivers around a music festival in south-west France in 2017. Forensic Sci Int. 2019; 297:265-269. DOI: 10.1016/j.forsciint.2019.02.029. View

15.

Kim J, Kwon W, Kim H, Suh S, In M . Estimation of measurement uncertainty for the quantification of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid and its glucuronide in urine using liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2014; 38(3):164-70. DOI: 10.1093/jat/bku008. View

16.

Laloup M, Ramirez Fernandez M, Wood M, De Boeck G, Henquet C, Maes V . Quantitative analysis of delta9-tetrahydrocannabinol in preserved oral fluid by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2005; 1082(1):15-24. DOI: 10.1016/j.chroma.2005.03.031. View

17.

Wiencek J, Colby J, Nichols J . Rapid Assessment of Drugs of Abuse. Adv Clin Chem. 2017; 80:193-225. DOI: 10.1016/bs.acc.2016.11.003. View

18.

Concheiro M, de Castro A, Quintela O, Cruz A, Lopez-Rivadulla M . Confirmation by LC-MS of drugs in oral fluid obtained from roadside testing. Forensic Sci Int. 2007; 170(2-3):156-62. DOI: 10.1016/j.forsciint.2007.03.034. View

19.

Manno J, Manno B, Kemp P, Alford D, Abukhalaf I, McWilliams M . Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol. 2001; 25(7):538-49. DOI: 10.1093/jat/25.7.538. View

20.

Drummer O, Gerostamoulos D, Chu M, Swann P, Boorman M, Cairns I . Drugs in oral fluid in randomly selected drivers. Forensic Sci Int. 2007; 170(2-3):105-10. DOI: 10.1016/j.forsciint.2007.03.028. View